TENAX THERAPEUTICS, INC. (TENX) research
TENAX THERAPEUTICS, INC.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.98
- As of
TENAX THERAPEUTICS, INC. (TENX): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-09.
As of . Source: SEC EDGAR filings for TENX. Method and limitations.
Share the TENX intelligence card
See the full TENX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TENX on one page. Preview it with sample data, then open it live with a free account.
Preview the TENX dossierActive signals for TENX
- highCONSENSUS_BUY
5 tracked funds increased TENX this 2026Q2, institutional consensus
- highCONSENSUS_BUY
3 tracked funds increased TENX this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +64% to TENX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +69% to TENX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +503% to TENX (2026Q2)
FREE, NO ACCOUNT
Every signal on TENX, as it fires
You are seeing 5 of 15 signals recorded on TENX since 2026-05-30.
The five above landed across 2 days. The other 10 were recorded on 4 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in TENX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 88032L605 · 2026Q2 | $12.7M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 88032L605 · 2026Q2 | $10.6M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 88032L605 · 2026Q2 | $8.1M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 88032L605 · 2026Q2 | $5.1M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 88032L605 · 2026Q2 | $2.4M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TENX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
TENX against its peers
TENX's return on equity of -54.2% ranks in the 68th percentile of 16 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-04-30.
| Metric | TENX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 35.6M USD | 8 | 11 |
| Operating margin | n/a | -72.6% | n/a | 10 |
| Net margin | n/a | -31.7% | n/a | 10 |
| Return on equity | -54.2% | -75.4% | 68 | 16 |
Peers (21): PMVP, FBIO, MAIA, OSTX, GANX, GOSS, CING, ALDX, RNXT, VRCA, SPRO, CSBR, KLRS, PTHS, HRTX, XBIT, ATRA, ONCY, GUTS, NTHI, ATHE. Left out: BSEM (no annual filing), OKYO (period gap), APLM (period gap), TELO (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (TENX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more TENX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to TENXand get the insider, 13F, options, and confluence read in one view.